KOMPAS.com - "Better than nothing."
That's one infectious disease expert's assessment of Sinovac Biotech's COVID-19 vaccine, following reports that hundreds of Indonesian health care workers who had received the vaccine caught the disease anyway.
It's unclear how widespread these "breakthrough" infections are. It's also not clear how severe most of the infections are. Little peer-reviewed data on the vaccine are available.
What information is available suggests that the vaccine is less potent than others, especially against the highly contagious delta variant that was first detected in India.
However, access to more effective vaccines is limited in much of the world, experts note. Indonesia is one of dozens of countries where the Chinese company's vaccine makes up a substantial part of the available doses.
While the shortage of published peer-reviewed data makes it hard to evaluate the vaccine, a few available studies provide a glimpse.
The government of Uruguay released data earlier this month showing CoronaVac reduced COVID-19 infections by 61%, hospitalizations by 92% and deaths by 95%.
Although not peer-reviewed, the study is one of a few that compare CoronaVac with another vaccine.